Attune Pharmaceuticals

About Attune Pharmaceuticals

Attune Pharmaceuticals operates as a clinical-stage biotechnology company with a clear focus on developing novel treatments for rare diseases. Founded in 2017 in New York City by Andrew McDonald, who also serves as the CEO, the company is committed to addressing underserved medical conditions through scientific advancement. The executive team's experience is noteworthy, with Chief Medical Officer Ira Kalfus, M.D., and Chief Operating Officer Jason Bablak having previously been involved in the development of Cinryze, a drug for Hereditary Angioedema (HAE).

The company's business model is centered on the discovery and clinical development of orally administered, small-molecule therapeutics. This approach targets diseases where current treatments are often invasive, such as intravenous or subcutaneous injections, aiming to improve patient quality of life. Attune's primary market is the rare disease sector, with a specific emphasis on conditions like HAE and other complement-mediated diseases. The company's financial strategy relies on venture capital funding to advance its drug candidates through the demanding phases of clinical trials. A significant milestone was achieved in 2018 and early 2019 when Attune secured $23.3 million in a Series B financing round. This funding was led by Venrock Healthcare Partners and included participation from LifeSci Venture Partners, RTW Investments, RA Capital, Boxer Capital, and Tang Capital.

Attune's lead product candidate is ATN-249, an oral plasma kallikrein inhibitor developed for the treatment of HAE. HAE is a rare genetic disorder that causes severe, unpredictable, and potentially life-threatening swelling episodes. The key benefit of ATN-249 is its oral, once-daily administration, which offers a significant advantage over existing injectable treatments. The development of ATN-249 was a considerable undertaking, involving the synthesis of over 1,200 compounds to achieve the desired oral bioavailability and therapeutic properties. Following promising preclinical safety studies, the company initiated Phase 1 clinical trials for ATN-249 in 2023 and 2025. Beyond HAE, Attune is expanding its research into other areas, including Paroxysmal Nocturnal Hemoglobinuria (PNH) and other diseases related to the complement pathway.